Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA approves Adcetris for first-line classical Hodgkin's lymphoma

FDA approved an sBLA from Seattle Genetics Inc. (NASDAQ:SGEN) for Adcetris brentuximab vedotin in combination with chemotherapy to treat adults with previously untreated stage

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE